CN109563049B - 作为eaat3抑制剂的咪唑化合物 - Google Patents

作为eaat3抑制剂的咪唑化合物 Download PDF

Info

Publication number
CN109563049B
CN109563049B CN201780045776.7A CN201780045776A CN109563049B CN 109563049 B CN109563049 B CN 109563049B CN 201780045776 A CN201780045776 A CN 201780045776A CN 109563049 B CN109563049 B CN 109563049B
Authority
CN
China
Prior art keywords
tert
butyl
benzamide
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780045776.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109563049A (zh
Inventor
马里乌斯·赫纳
于尔根·维希曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN109563049A publication Critical patent/CN109563049A/zh
Application granted granted Critical
Publication of CN109563049B publication Critical patent/CN109563049B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201780045776.7A 2016-10-14 2017-10-11 作为eaat3抑制剂的咪唑化合物 Expired - Fee Related CN109563049B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16193871 2016-10-14
EP16193871.7 2016-10-14
PCT/EP2017/075875 WO2018069362A1 (en) 2016-10-14 2017-10-11 Imidazole compounds as eaat3 inhibitors

Publications (2)

Publication Number Publication Date
CN109563049A CN109563049A (zh) 2019-04-02
CN109563049B true CN109563049B (zh) 2022-11-29

Family

ID=57136749

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780045776.7A Expired - Fee Related CN109563049B (zh) 2016-10-14 2017-10-11 作为eaat3抑制剂的咪唑化合物

Country Status (5)

Country Link
US (1) US10556870B2 (cg-RX-API-DMAC7.html)
EP (1) EP3526201B1 (cg-RX-API-DMAC7.html)
JP (1) JP7068277B2 (cg-RX-API-DMAC7.html)
CN (1) CN109563049B (cg-RX-API-DMAC7.html)
WO (1) WO2018069362A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882926A (en) * 1993-10-20 1999-03-16 Oregon Health Sciences University Excitatory amino acid transporter gene and uses
WO2009077365A1 (en) * 2007-12-17 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazole-substituted arylamides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006151954A (ja) 2004-10-27 2006-06-15 Taisho Pharmaceut Co Ltd アスパラギン酸誘導体
US7939556B2 (en) 2005-10-14 2011-05-10 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
ES2596706T3 (es) 2006-06-29 2017-01-11 F. Hoffmann-La Roche Ag Arilamidas con sustitución de tetrazol
KR101186704B1 (ko) 2007-10-04 2012-09-27 에프. 호프만-라 로슈 아게 테트라졸-치환된 아릴 아마이드 유도체 및 이의 용도
WO2009058298A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain
KR101405746B1 (ko) 2007-12-17 2014-06-10 에프. 호프만-라 로슈 아게 트리아졸 치환된 아릴아미드 유도체 및 p2x3 및/또는 p2x2/3 퓨린성 수용체 길항제로서의 용도
DK2234976T3 (da) 2007-12-17 2013-06-24 Hoffmann La Roche Nye pyrazol-substituerede arylamider
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
CA2741666C (en) 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
EP3542813A1 (en) * 2013-05-31 2019-09-25 The A2 Milk Company Limited Beta-casein a2 and prevention of inflammation of the bowel
CN105555766A (zh) * 2013-07-18 2016-05-04 诺华股份有限公司 作为补体因子d抑制剂的氨基甲基-联芳基衍生物及其应用
US10577332B2 (en) 2015-04-23 2020-03-03 Hoffmann-La Roche Inc. Tetrazole derivatives
CN107531642B (zh) 2015-06-04 2021-06-22 豪夫迈·罗氏有限公司 咪唑衍生物
JP6846363B2 (ja) 2015-07-14 2021-03-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 2−フェニル−6−イミダゾリル−ピリジン−4−カルボキサミド誘導体及びそのeaat3阻害剤としての使用
WO2017025523A1 (en) 2015-08-12 2017-02-16 F. Hoffmann-La Roche Ag Pyridine and pyrimidine derivatives
WO2017060202A1 (en) 2015-10-06 2017-04-13 F. Hoffmann-La Roche Ag Triazole derivatives
ITUB20154829A1 (it) 2015-10-27 2017-04-27 Giuseppe Galtieri Dispositivo ad impulsi dinamici da traffico veicolare e relativo kit.
EP3411365B1 (en) 2016-02-02 2019-11-20 H. Hoffnabb-La Roche Ag Pyrazol-pyridine derivatives as eaat3 inhibitors
CN109071451B (zh) 2016-05-27 2022-07-15 豪夫迈·罗氏有限公司 作为eaat3抑制剂的吡唑化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882926A (en) * 1993-10-20 1999-03-16 Oregon Health Sciences University Excitatory amino acid transporter gene and uses
WO2009077365A1 (en) * 2007-12-17 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazole-substituted arylamides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis and preliminary pharmacological evaluation of novel derivatives of L-b-threo-benzylaspartate as inhibitors of the neuronal glutamate transporter EAAT3;Terri L. Mavencamp,等;《Bioorganic & Medicinal Chemistry》;20080808;7740-7748 *
The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes;Richard J. Bridges,等;《Pharmacology & Therapeutics》;20050901;第107卷(第3期);271-285 *

Also Published As

Publication number Publication date
JP2019532050A (ja) 2019-11-07
US10556870B2 (en) 2020-02-11
EP3526201A1 (en) 2019-08-21
WO2018069362A1 (en) 2018-04-19
CN109563049A (zh) 2019-04-02
EP3526201B1 (en) 2020-11-18
JP7068277B2 (ja) 2022-05-16
US20190233379A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
CN107207449B (zh) 用于治疗精神障碍的四唑衍生物
CN107922391B (zh) 吡啶和嘧啶衍生物
CN107531642A (zh) 咪唑衍生物
CN107922381B (zh) 吡啶或嘧啶衍生物
TW200416030A (en) Therapeutic proline derivatives
CN108137566B (zh) 三唑衍生物
EP3411365B1 (en) Pyrazol-pyridine derivatives as eaat3 inhibitors
CN109071451B (zh) 作为eaat3抑制剂的吡唑化合物
US10556870B2 (en) Imidazole compounds as EAAT3 inhibitors
HK40004826B (en) Imidazole compounds as eaat3 inhibitors
HK40004826A (en) Imidazole compounds as eaat3 inhibitors
HK1262810A1 (en) Pyrazol compounds as eaat3 inhibitors
HK1262810B (en) Pyrazol compounds as eaat3 inhibitors
HK1254202B (en) Triazole derivatives
HK1245269B (en) Imidazole derivatives
HK1247192B (en) Pyridine or pyrimidine derivatives
HK1251226B (en) Pyridine and pyrimidine derivatives
HK1241878B (en) Tetrazole derivatives for use in the treatment of psychiatric disorders
HK1252767B (en) Pyrazol-pyridine derivatives as eaat3 inhibitors
HK1250028B (en) 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004826

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20221129